SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors

  • SQZ Biotechnologies Company SQZ announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Human Papillomavirus positive (HPV16+) solid tumors. 
  • The investigational cell therapy is being evaluated in certain patients with advanced or metastatic HPV16+ cancers.
  • In an abstract published, a heavily treated patient in the highest-dose cohort demonstrated a radiographic response in conjunction with substantial increases in CD8 T cell tumor infiltration and PD-L1 expression, both markers of tumor inflammation. 
  • The cell therapy was generally well-tolerated, and no dose-limiting toxicities were observed.
  • The highest-dose monotherapy stage continues enrollment to further characterize the investigational therapy in single-agent settings.
  • Price Action: On the last check Thursday, SQZ shares traded 5.45% lower at $11.63.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialPhase 2 TrialSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!